Conversely, NSCLC patients with MET exon 14 alterations (METex14) demonstrate a lower overall response rate to immune checkpoint blockade and a shorter median progression-free survival, despite the majority of patients expressing PD-L1 [201]. Here, MET is linked to non-small cell lung carcinoma.